The new edition of the 2016 World Health Organization (WHO) classification system for
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …

This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …

Background Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical
benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open …

Ruxolitinib is a Janus kinase (JAK)(JAK1/JAK2) inhibitor that has demonstrated superiority
over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with …

Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is
currently based on clinically‐derived variables; we examined the possibility of integrating …

Overview: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent
myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often …

A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …